Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library

Tirzepatide vs survodutide

Tirzepatide and survodutide both activate the GLP-1 receptor, but tirzepatide pairs it with the GIP receptor while survodutide pairs it with the glucagon receptor 1,2. Tirzepatide is FDA-approved as Mounjaro and Zepbound 3. Survodutide is investigational: its phase 3 obesity results were published in 2026, and no Drugs@FDA application record was returned on 24 October 2026 2,4. No head-to-head trial was identified 5.

Unbranded reference vial illustrating Tirzepatide; not an actual product
Tirzepatide
FDA-approved
Unbranded reference vial illustrating Survodutide; not an actual product
Survodutide
Investigational

Side by side

FieldTirzepatideSurvodutide
ClassDual GIP receptor and GLP-1 receptor agonist 1Dual glucagon receptor and GLP-1 receptor agonist (investigational) 2
Origin and structureSynthetic peptide based on the GIP sequence with a C20 fatty diacid attached at lysine 20; molecular weight 4813.53 Da 1Acylated peptide carrying a C18 fatty acid as a half-life-extending element 6
Proposed mechanismActivates GIP and GLP-1 receptors; label describes glucose-dependent insulin secretion and lower glucagon levels 1In mice, reduced food intake and increased energy expenditure, with engagement of both glucagon and GLP-1 receptors 6
Half-lifeAbout 5 days (Mounjaro label); about 5 to 6 days in overweight or obesity (Zepbound label) 1,7Not located in the sources reviewed
Highest human trial phaseApproved; phase 3 programme published 8,9Phase 3 (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-MASLD) 2,10,11
FDA statusApproved as Mounjaro (13 May 2022) and Zepbound (8 November 2023), per Drugs@FDA as of 24 October 2026 3Not approved; no Drugs@FDA application record as of 24 October 2026 4
Published human outcomesSURMOUNT-1: -15.0% to -20.9% vs -3.1% with placebo at 72 weeks 8; reduced apnea-hypopnea index in SURMOUNT-OSA 9SYNCHRONIZE-1: -12.2% and -13.0% vs -5.4% at 76 weeks 2; SYNCHRONIZE-2 (type 2 diabetes): -8.2% and -9.8% vs -3.9% 10; liver-fat reductions in SYNCHRONIZE-MASLD 11
Safety signalsBoxed warning for thyroid C-cell tumours in rats; most common adverse reactions gastrointestinal 1Gastrointestinal events in 80.9% and 89.7% vs 47.9% with placebo in SYNCHRONIZE-1 2; nausea 66% vs 23% in the MASH phase 2 trial 12
WADA statusNot named on the 2026 Prohibited List 13; GLP-1 receptor agonist status unchanged for 2027 per WADA 14Not named on the 2026 Prohibited List; class S0 covers drugs under clinical development with no current approval by any governmental health authority 13
Who funded the evidenceEli Lilly 8,9Boehringer Ingelheim 2,10

Tirzepatide: what the data says

Tirzepatide is FDA-approved for type 2 diabetes and cardiovascular risk reduction in high-risk adults with type 2 diabetes (Mounjaro), and for chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound) 1,7.

  • In SURMOUNT-1 (2539 adults without diabetes; human data), mean body-weight change at 72 weeks was -15.0% to -20.9% vs -3.1% with placebo 8.
  • In SURMOUNT-OSA (human data), the apnea-hypopnea index fell by 20.0 and 23.8 more events per hour than with placebo in the two trials 9.

Survodutide: what the data says

Survodutide's evidence comes from a Boehringer Ingelheim programme spanning obesity, type 2 diabetes and liver disease 2,10,12.

  • In SYNCHRONIZE-1 (725 adults; human data), mean body-weight change at 76 weeks was -12.2% and -13.0% vs -5.4% with placebo; no deaths were reported 2.
  • In SYNCHRONIZE-MASLD (216 adults; human data), 84.2% vs 24.3% had at least a 30% fall in MRI-measured liver fat at 48 weeks (efficacy estimand) 11.
  • In a phase 2 MASH trial (human data), improvement in MASH without worsening of fibrosis occurred in 43% to 62% vs 14% with placebo 12.

Key research differences

  • Second receptor target: GIP receptor for tirzepatide vs glucagon receptor for survodutide 1,2.
  • Regulatory status: tirzepatide has FDA approvals from 2022 and 2023, while survodutide had no Drugs@FDA record on 24 October 2026 3,4.
  • Liver focus: survodutide has published MASLD phase 3 and MASH phase 2 trials 11,12, while tirzepatide's FDA labels list diabetes, weight-management, cardiovascular and sleep-apnea indications 1,7.
  • Half-life data: the tirzepatide label gives about 5 days, whereas no numeric human half-life for survodutide was located 1.
  • Developers: tirzepatide trials were funded by Eli Lilly and survodutide trials by Boehringer Ingelheim 2,8.

Where the evidence is limited

No randomized trial has compared tirzepatide and survodutide directly in the sources reviewed 5. SURMOUNT-1 and SYNCHRONIZE-1 differ in duration (72 vs 76 weeks), placebo-group change (-3.1% vs -5.4%) and statistical estimands, so cross-trial differences in percentages are not a reliable guide 2,8.

Frequently asked questions

Does tirzepatide lead to more body-weight change than survodutide?
This cannot be determined from the evidence reviewed. No head-to-head trial exists, and the phase 3 trials of each used different durations and had different placebo responses 2,5,8.
Is survodutide FDA-approved?
No. An openFDA query of Drugs@FDA on 24 October 2026 returned no application record, and its 2026 phase 3 reports call it investigational 2,4.
How do tirzepatide and survodutide differ in mechanism?
Both activate the GLP-1 receptor. Tirzepatide also activates the GIP receptor, while survodutide also activates the glucagon receptor, which in mice was linked to increased energy expenditure 1,6.

References

  1. MOUNJARO (tirzepatide) injection: prescribing information, DailyMed set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0 (label version dated 27 August 2026) FDA label (via openFDA). 2026
  2. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1) N Engl J Med. 2026
  3. Drugs@FDA application records for NDA 215866 (Mounjaro), NDA 217806 (Zepbound), NDA 209637 (Ozempic), NDA 215256 (Wegovy), NDA 022341 (Victoza) and NDA 206321 (Saxenda): original approval dates (queried 24 October 2026) Drugs@FDA (via openFDA). 2026
  4. Drugs@FDA application data queried through openFDA for survodutide (no matching application record returned on 24 October 2026) openFDA / Drugs@FDA. 2026
  5. ClinicalTrials.gov registry search for survodutide as intervention (29 records, 12 phase 3; retrieved 24 October 2026) ClinicalTrials.gov. 2026
  6. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy Mol Metab. 2022
  7. ZEPBOUND (tirzepatide) injection: prescribing information, DailyMed set ID 487cd7e7-434c-4925-99fa-aa80b1cc776b (label version dated 28 August 2026) FDA label (via openFDA). 2026
  8. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) N Engl J Med. 2022
  9. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) N Engl J Med. 2024
  10. Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2) N Engl J Med. 2026
  11. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Nat Med. 2026
  12. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis N Engl J Med. 2024
  13. The 2026 Prohibited List - World Anti-Doping Code, as published in the Netherlands Treaty Series (Tractatenblad 2026, 25; Council of Europe Anti-Doping Convention appendix, in force 1 January 2026) Tractatenblad (Official Publications of the Kingdom of the Netherlands). 2026
  14. WADA publishes 2027 Prohibited List (news release, 21 September 2026) World Anti-Doping Agency. 2026

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.